Table 3.

Correlation between PFS and clinical data by univariate analysis

Item	PFS (months)	P value
Age
<60.0	4.0 ± 0.21	0.419
≥60.0	5.0 ± 0.62
ER
Negative	4.0 ± 0.55	0.025
Positive	5.0 ± 0.47
PR
Negative	4.0 ± 0.52	0.345
Positive	4.0 ± 0.49
HER2
Negative	4.0 ± 0.18	0.209
Positive	5.0 ± 0.57
Metastatic site
Visceral	4.0 ± 0.59	0.785
Skin/lymph/bone	5.0 ± 0.78
Both	4.0 ± 0.28
Menopausal Status
Premenopause	4.0 ± 0.74	0.238
Post-menopause	4.0 ± 0.31
Pre-chemotherapy (vs.)
≤3 cycles	4.0 ± 0.31	0.788
>3 cycles	4.0 ± 1.13
CD8+CD28+
<11.0 %	4.0 ± 0.34	0.029
≥11.0 %	6.0 ± 0.73
CD8+CD28−
<24.0 %	5.0 ± 0.50	<0.001
≥24.0 %	3.0 ± 0.25
CD4+CD25+
<9.6 %	4.0 ± 0.22	0.236
≥9.6 %	5.0 ± 0.68
CD3+
<59.1 %	4.0 ± 0.68	0.717
≥59.1 %	4.0 ± 0.38
CD3+CD4+
<32.5 %	4.0 ± 0.30	0.015
≥32.5 %	5.0 ± 0.53
CD3+CD8+
<23.7 %	5.0 ± 0.58	0.419
≥23.7 %	4.0 ± 0.19
CD3−CD16+56+
<16.9 %	5.0 ± 0.50	0.703
≥16.9 %	4.0 ± 0.34
CD19+
<13.6 %	4.0 ± 0.39	0.674
≥13.6 %	4.0 ± 0.66

P values were determined by log-rank test

ER estrogen receptor, PR progesterone receptor, PFS progression-free survival